Puede usar las teclas derecha/izquierda para votar el artículo.Votación:1 estrella2 estrellas3 estrellas4 estrellas5 estrellas (2 votos, promedio: 4.00 sobre 5)

Health Nivel B2

Oxford clinical trials restart after halt to probe volunteer illness

By Viviana García / London / Clinical trials for a Covid-19 vaccine being carried out by Oxford University and AstraZeneca have restarted after a temporary halt was ordered when one of the volunteers fell ill.

The vaccine being developed at the prestigious university is one of the most promising of the numerous research projects being conducted around the world.

Scientists are scrambling to find a functioning vaccine for Covid-19 to curb the pandemic that has so far infected at least 28 million people and killed 900,000 around the world.

In a statement, Oxford University confirmed clinical trials would restart after a precautionary pause on 6 September. It was given the go-ahead by the Medicines Health Regulatory Authority.

The vaccine is in the final stages of clinical trials, the last step before regulators approve its use on the general population.

The European Union on 14 August announced it had signed a contract with AstraZeneca to guarantee 300 million orders of an eventual vaccine. The pause in the clinical trials sparked concern in Europe and further afield.

Oxford University confirmed in its statement that 18,000 volunteers around the world have received a dose of the CHAdOx1 nCoV-19 vaccine as part of its clinical trials and, given the scope of the research, illnesses by chance were likely.

“The ongoing randomized controlled clinical trials of the Oxford coronavirus vaccine CHAdOx1 nCoV-19 will resume across all UK clinical trial sites,” the statement said.

“In large trials such as this, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.”

The company did not comment on the nature of the illness picked up by the volunteer due to patient confidentiality.

The vaccine is being tested in the United Kingdom, the United States, Brazil and South Africa.

Last month the governments of Argentina and Mexico signed a deal with AstraZeneca and Oxford University to create vaccines in their country for distribution around Latin America.

Argentina’s president Alberto Fernández said the objective was to create between 150-250 million doses that would cost between $3-$4 each.

The EU said it would distribute any future vaccine from AstraZeneca to its member states depending on the population of each country. (September 12, 2020, EFE/PracticaEspañol)

The related news in video (September 9, 2020):


Lee la noticia y responde a las preguntas

Congratulations - you have completed Lee la noticia y responde a las preguntas.

You scored %%SCORE%% out of %%TOTAL%%.

Your performance has been rated as %%RATING%%

Your answers are highlighted below.
Question 1
En el texto se dice que...
se desmiente que los ensayos clínicos de esa vacuna se hayan interrumpido.
los ensayos clínicos de esa vacuna no fueron interrumpidos a pesar de la reacción adversa que tuvo un voluntario.
continuarán los ensayos clínicos de esa vacuna después de haber sido interrumpidos durante un tiempo.
Question 2
Según el texto...
los ensayos clínicos de esa vacuna que está desarrollando la universidad de Oxford están en las fases finales.
ya se está vacunando a toda la población con la vacuna que ha desarrollado la universidad de Oxford.
Oxford está comenzado a desarrollar una vacuna contra la COVID-19.
Question 3
En el texto se dice que...
aún la UE no ha llegado a ningún acuerdo con la farmacéutica AstraZeneca para garantizar las dosis de esa vacuna a la población.
los ensayos clínicos se reanudarán después de que el MHRA dé el visto bueno.
la vacuna que está desarrollando la universidad de Oxford solo se está probando en Reino Unido.
Question 4
Leyendo el texto entendemos que...
AstraZeneca espera que la vacuna esté ya lista a finales de año.
no es cierto que AstraZeneca y Oxford hayan llegado a un acuerdo con México en relación con la fabricación y distribución de esa vacuna.
se desmiente que se estén desarrollando varias vacunas contra la COVID-19 en todo el mundo.
Question 5
Esa vacuna que están desarrollando proporciona doble protección contra la COVID-19.
¡Imposible saberlo!
Así es.
Para nada.
Question 6
En el vídeo se ve que...
no solo los voluntarios sino todos los investigadores llevan la mascarilla puesta para protegerse de la COVID-19.
ningún investigador utiliza guantes cuando está trabajando en el laboratorio.
hay investigadores que utilizan unas gafas protectoras.
Once you are finished, click the button below. Any items you have not completed will be marked incorrect. Get Results
There are 6 questions to complete.

Noticias al azar

Multimedia news of Agencia EFE to improve your Spanish. News with text, video, audio and comprehension and vocabulary exercises.